IL-2

Home
Ligands
IL-2 (Human)

GtoPdb Ligand ID: 4985

Synonyms: aldesleukin | interleukin-2 | Proleukin®

IL-2 is an approved drug (FDA (1992))

Compound class: Endogenous peptide in human, mouse or rat

Comment: IL-2 and IL-15 are cytokines that share common biological effects, but also exhibit distinct, and sometimes competing, functions [6]. Recombinant IL-2 is used clinically with the generic name aldesleukin.
Abbas et al. (2018) have written a review of IL-2 biology and the progress that has been made in developing IL-2 therapeutics [1].

Species: Human

View more information in the IUPHAR Pharmacology Education Project: interleukin-2

References
1. Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. (2018) Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol, 3 (25). [PMID:29980618]
2. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, Yu C, Arkin MR, Raimundo BC. (2003) Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J Am Chem Soc, 125 (13): 3714-5. [PMID:12656598]
3. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 6 (11): 1142-51. [PMID:16227984]
4. Klatzmann D, Abbas AK. (2015) The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol, 15 (5): 283-94. [PMID:25882245]
5. Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL et al.. (2018) A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat Med, 24 (7): 1005-1014. [PMID:29942088]
6. Waldmann TA. (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol, 6 (8): 595-601. [PMID:16868550]

References

1. Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. (2018)
Revisiting IL-2: Biology and therapeutic prospects.
Sci Immunol, 3 (25). [PMID:29980618]

2. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, Waal N, Yu C, Arkin MR, Raimundo BC. (2003)
Discovery of a potent small molecule IL-2 inhibitor through fragment assembly.
J Am Chem Soc, 125 (13): 3714-5. [PMID:12656598]

3. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. (2005)
A function for interleukin 2 in Foxp3-expressing regulatory T cells.
Nat Immunol, 6 (11): 1142-51. [PMID:16227984]

4. Klatzmann D, Abbas AK. (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.
Nat Rev Immunol, 15 (5): 283-94. [PMID:25882245]

5. Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL et al.. (2018)
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.
Nat Med, 24 (7): 1005-1014. [PMID:29942088]

6. Waldmann TA. (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
Nat Rev Immunol, 6 (8): 595-601. [PMID:16868550]